These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16154711)

  • 1. Aromatase inhibitors may be effective in the management of advanced hepatocellular carcinoma.
    Altundag O; Altundag K; Turen S; Gunduz E; Atik MA
    Med Hypotheses; 2006; 66(6):1257. PubMed ID: 16154711
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
    Cipriani G; Mazzanti R
    Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of somatostatin analogs in the management of hepatocellular carcinoma.
    D'Agostino L; Manguso F; Pivonello R; Colao A
    J Endocrinol Invest; 2003; 26(8 Suppl):131-3. PubMed ID: 15233229
    [No Abstract]   [Full Text] [Related]  

  • 5. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can metallothionein be a useful molecular marker for selecting hepatocellular carcinoma patients for platinum-based chemotherapy?
    Doki Y; Monden M
    J Gastroenterol; 2004 Dec; 39(12):1228-9. PubMed ID: 15622495
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Liu et al.--Estrogen receptor status in inoperable hepatocellular carcinoma.
    Chow PK; Hung H; Soo KC
    Am J Gastroenterol; 2001 Apr; 96(4):1297-8. PubMed ID: 11316190
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials.
    Yeo W; Mo FK; Hui P; Chan SL
    Contemp Clin Trials; 2010 Mar; 31(2):135. PubMed ID: 20123038
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting chemokines as a therapeutic option for hepatocellular carcinoma: a reality or just a fantasy?
    Yu J
    J Gastroenterol Hepatol; 2007 May; 22(5):611-2. PubMed ID: 17444845
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting vessels to treat hepatocellular carcinoma.
    Romanque P; Piguet AC; Dufour JF
    Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-mediated protection of normal hepatocytes during chemotherapy for hepatocellular carcinoma.
    Keegan-Rogers V; Wu CH; Wu GY
    Targeted Diagn Ther; 1991; 4():105-25. PubMed ID: 1665717
    [No Abstract]   [Full Text] [Related]  

  • 13. Growth inhibition and gene induction in human hepatocellular carcinoma cell exposed to sodium 4-phenylbutanoate.
    Wang CT; Meng M; Zhang JC; Jin CJ; Jiang JJ; Ren HS; Jiang JM; Qin CY; Yu DQ
    Chin Med J (Engl); 2008 Sep; 121(17):1707-11. PubMed ID: 19024104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial: Hepatoma: a challenging disease.
    Umsawasdi T
    J Med Assoc Thai; 1976 Mar; 59(3):95-9. PubMed ID: 177711
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant treatments for resectable hepatocellular carcinoma.
    Ishii H; Yamamoto J; Ikari T
    J Hepatobiliary Pancreat Surg; 2008; 15(5):459-62. PubMed ID: 18836796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy for hepatocellular carcinoma].
    Okada S
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():645-9. PubMed ID: 11762028
    [No Abstract]   [Full Text] [Related]  

  • 19. [The effect and pharmacokinetics of etoposide in patients with primary hepatocellular carcinoma].
    Funakoshi S; Aiba K; Dobashi F; Inamoto Y; Hirano A; Tada N; Ogihara A; Fujii T; Kuraishi Y; Yamada T
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):165-7. PubMed ID: 8380686
    [No Abstract]   [Full Text] [Related]  

  • 20. Growth factors as therapeutic targets in HCC.
    Furuse J
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.